Uso terapéutico del Cannabis sativa en el tratamiento dela Enfermedad de Alzheimer: revisión integradora
DOI:
https://doi.org/10.11606/issn.1806-6976.smad.2025.227069Palabras clave:
Enfermedad de Alzheimer, Cannabis, Marihuana Medicinal, Manifestaciones NeuroconductualesResumen
Objetivo: investigar, a la luz de la literatura científica, la eficacia del uso terapéutico del Cannabis sativa en el tratamiento del Alzheimer. Metodología: revisión integradora de la literatura que reunió artículos sobre la base de una metodología sistematizada. La búsqueda de estudios se llevó a cabo a través de las bases de datos Literatura Latinoamericana y del Caribe en Ciencias de la Salud, SciVerse Scopus y Web of Science, utilizando Descriptores de Ciencias de la Salud. Resultados: la muestra incluyó 16 artículos científicos, que indicaban una tendencia creciente en la exploración de compuestos de Cannabis sativa para el tratamiento sintomático de la
enfermedad. En los hallazgos se destacan los estudios experimentales en el laboratorio, así como el análisis de la dosis no tóxica ideal para la eficacia del tratamiento. La eficacia del tratamiento se demuestra por el retraso y/o reducción de los síntomas conductuales de la enfermedad con la consiguiente mejora de la calidad del contexto familiar implicado. Conclusión: el uso de compuestos de Cannabis sativa demostró eficacia para el tratamiento sintomático de personas con Alzheimer, lo que revela un avance de la medicina y una ruptura de paradigmas respecto a la planta. La evidencia presentada demuestra matices específicos que pueden impactar no sólo en la vida de la persona que padece la enfermedad, sino en toda la dinámica familiar.
Descargas
Referencias
Araújo SEM, Cunha ER. Marques IL. Paixão AS, Dias AFG. Sousa PM, et al. Alzheimer's disease in Brazil: an epidemiological analysis between 2013 and 2022. Res Soc Dev. 2023;12(2):1-6. https://doi.org/10.33448/rsd-v12i2.40345
Watt G, Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Front Pharmacol. 2017;8:20. https://doi.org/10.3389/fphar.2017.00020
Santos VRT, Santos RA, Guedes JPM, Andrade MC. The use of cannabis in the treatment of Alzheimer. Res Soc Dev. 2022;11(7):e28711729889. https://doi.org/10.33448/rsd-v11i7.29889
Remor KVT, Fraga AC, Mazzucchetti L, Blatt CR, Sakae TM. Alzheimer disease: pharmacological treatment and cognitive performance. Rev AMRIGS [Internet]. 2020 [cited 2024 Jun 11];64(2):207-12. Available from: https://oldsite.amrigs.org.br/assets/images/upload/pdf/jornal/1610631629.pdf#page=41
Costa BGL, Lima LR, Funghetto SS, Volpe CRG, Santos WS, Stival MM. Non-pharmacological methods for Alzheimer’s treatment: na integrative review. Rev Enferm Cent-Oeste Min. 2019;9. https://doi.org/10.19175/recom.v9i0.2786
Pessoa DOC, Lira IV, Siqueira LDP. Cannabis Sativa: an integrative review of legal, toxicological and pharmacotherapeutic aspects. Res Soc Dev. 2021;10(15):e18101522408. https://doi.org/10.33448/rsd-v10i15.22408
Sousa IGD, Marques NM. Descobertas sobre o uso de cannabis na doença de Alzheimer: uma revisão da literatura. In: Anais do VI Congresso Internacional de Envelhecimento Humano. [Internet]; 2019 Jun 26-28; Campina Grande, PB. Campina Grande: Realize Eventos; 2019 [cited 2023 Nov 16]. Available from: https://www.editorarealize.com.br/editora/anais/cieh/2019/TRABALHO_EV125_MD4_SA2_ID2756_27052019222514.pdf
Casarin ST, Porto AR, Gabatz RIB, Bonow CA, Ribeiro JP, Mota MS. Types of literature review: considerations of the editors of the Journal of Nursing and Health. J Nurs Health [Internet]. 2020 [cited 2023 Nov 27];10(5). https://doi.org/10.15210/jonah.v10i5.19924
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4
Agency for Healthcare Research and Quality. Introduction to the Toolkit for using the AHRQ Quality Indicators: how to improve hospital quality and safety [Internet]. Rockville, MD: AHRQ; 2016 [cited 2023 Sept 23]. Available from: https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/hospital/qitoolkit/combined/combined_toolkit.pdf
Bardin L. Análise de Conteúdo. São Paulo: Edições 70; 2016. 288 p.
Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β- amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:8. https://doi.org/10.1186/1742-2094-9-8
Coles M, Watt G, Kreilaus F, Karl T. Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APPSwe/PS1ΔE9 Transgenic Female Mice. Front Pharmacol. 2020;11. https://doi.org/10.3389/fphar.2020.587604
Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease. Mol Neurobiol. 2019;56(11):7719-30. https://doi.org/10.1007/s12035-019-1637-8
Libro R, Diomede F, Scionti D, Piattelli A, Grassi G, Pollastro F, et al. Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016;18(1):26. https://doi.org/10.3390/ijms18010026
Hermush V, Ore L, Stern N, Mizrahi N, Fried M, Krivoshey M, et al. Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Front Med. 2022;9. https://doi.org/10.3389/fmed.2022.951889
Leszko M, Meenrajan S. Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer’s disease. Complement Ther Med. 2021;57:102660. https://doi.org/10.1016/j.ctim.2021.102660
Broers B, Patà Z, Mina A, Wampfler J, de Saussure C, Pautex S. Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva. Med Cannabis Cannabinoids. 2019;2(1):56-9. https://doi.org/10.1159/000498924
Fihurka O, Wang Y, Hong Y, Lin X, Shen N, Yang H, et al. Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer’s Disease. Biomolecules. 2023;13(2):232. https://doi.org/10.3390/biom13020232
Chesworth R, Cheng D, Staub C, Karl T. Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model. Front Pharmacol. 2022;13. https://doi.org/10.3389/fphar.2022.931384
Nitzan K, Ellenbogen L, Bentulila Z, David D, Franko M, Break EP, et al. An Ultra- Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model. Int J Mol Sci. 2022;23(16):9449. https://doi.org/10.3390/ijms23169449
Bittes YP, Ribeiro LB, Anselmo GS, Dantas TCL, Ferreira MVR, Neves WC, et al. Uso dos canabinoides no tratamento de pessoas portadoras de Alzheimer. REVISA [Internet]. 2021 [cited 2023 Oct 13];10(2):887-99. Available from: https://rdcsa.emnuvens.com.br/revista/article/view/467
Timler A, Bulsara C, Bulsara M, Vickery A, Jacques A, Codde J. Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial. Australas J Ageing. 2023;42(4):698-709. https://doi.org/10.1111/ajag.13224
Ruver-Martins AC, Bicca MA, Araujo FS, Maia BHLNS, Pamplona FA, Silva EG, et al. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report. J Med Case Reports. 2022;16(1):277. https://doi.org/10.1186/s13256-022-03457-w
Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and Practices of Cannabis Dispensary Staff. Cannabis Cannabinoid Res. 2016;1(1):244-51. https://doi.org/10.1089/can.2016.0024
Ahmed AIA, van den Elsen GAH, Colbers A, Kramers C, Burger DM, van der Marck MA, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl). 2015;232(14):2587-95. https://doi.org/10.1007/s00213-015-3889-y
Seniya C, Khan GJ, Uchadia K. Identification of Potential Herbal Inhibitor of Acetylcholinesterase Associated Alzheimer’s Disorders Using Molecular Docking and Molecular Dynamics Simulation. Biochem Res Int. 2014;2014:e705451. https://doi.org/10.1155/2014/705451
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 SMAD, Revista Eletrônica Saúde Mental Álcool e Drogas (Edição em Português)
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
